S.TateM.ZhaoY.LockhartS.CalderwoodD.et al (2015)
Central nervous system effects: GLP-1 receptors are present in the brain, and their activation is hypothesised to influence neurological pathways associated with energy levels and alertness, though this mechanism has not been fully established in humans
tirzepatide approximately 1 month before)
Injectables: semaglutide and tirzepatide Injectable GLP-1 treatments are given subcutaneously, usually once weekly for semaglutide or tirzepatide
small absolute numbers) Palpitations: up to 3.2% (12 mg) Sinus tachycardia: up to 3.2% (12 mg) QT prolongation on ECG: 1.6% (12 mg) Retatrutide's Heart Rate Effects and Arrhythmia Risk in Obesity Trials Retatrutide and Cardiac Rhythm Safety Dose-Dependent Heart Rate Increase With Low Incidence of Clinically Significant Arrhythmias in Phase 2 Obesity Trials Background Retatrutide (LY3437943) is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, developed for the treatment of obesity and cardiometabolic disease
Hydration targets: 64-80 ounces of water daily, spread throughout the day
